Arquivo de 2021 - Núcleo de Investigação em Políticas Económicas e Empresariais

Rosa-Branca Esteves and Francisco Carballo Cruz. Can data openness unlock competition when the incumbent has exclusive data access for personalized pricing?.

J. Jerónimo and Assis de Azevedo and P. Neves and M. Thompson. Interactions between Financial Constraints and Economic Growth.

Susana Campos-Martins and Cristina Amado. Modelling Time-Varying Volatility Interactions.

Paulo Bastos and Natália P. Monteiro and Odd Rune Straume. The Division of Unexpected Revenue Shocks.

Julien Pinter. Monetarist arithmetic at Covid-19 time: a take on how not to misapply the quantity theory of money.

Israel J. S. Felipe and W. Mendes-Da-Silva and C. Cerqueira Leal and D. B. Santos. Reward Crowdfunding Campaigns: Time-To-Success Analysis.

Kurt R. Brekke and Luigi Siciliani and Odd Rune Straume. Competition, quality and integrated health care.

Rosa-Branca Esteves. Can personalized pricing be a winning strategy in oligopolistic markets with heterogeneous demand customers? Yes, it can..

Fernando Alexandre. Avaliação dos incentivos financeiros às empresas em Portugal: QREN (2007-2013) e PT2020 (2014-2018).

Luís Aguiar-Conraria and Gilmar Conceição and Maria Joana Soares. How far is gas from becoming a global commodity?.

Gilberto Loureiro and Sónia Silva. The Impact of Securities Regulation on the Information Environment around Stock-Financed Acquisitions.

João Martins and Linda Veiga and Bruno Fernandes. Does electronic government deter corruption? Evidence from across the world..

Rosa Branca Esteves and Francisco Carballo Cruz. Access to Data for Personalized Pricing: Can it raise entry barriers and abuse of dominance concerns?.

Ziad Ghandour and Luigi Siciliani and Odd Rune Straume. Investment and Quality Competition in Healthcare Markets.

Rosa-Branca Esteves and Qihong Liu and Jie Shuai. Behavior-Based Price Discrimination with Non-Uniform Distribution of Consumer Preferences.

Kurt R. Brekke and Dag Morten Dalen and Odd Rune Straume. Paying for pharmaceuticals: Uniform pricing versus two-part tariffs.

Manage cookies